Literature DB >> 1903312

Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas.

O Prümmer1, N Frickhofen, W Digel, H Heimpel, F Porzsolt.   

Abstract

High-titered spontaneous interferon (IFN) antibodies were detected in a patient with pure red cell aplasia (PRCA), a benign mediastinal tumor, and recurrent cutaneous carcinomas. The circulating IFN antibodies reacted broadly with various human IFN-alpha subtypes (20-140 x 10(3) neutralizing units/ml serum) but not with IFN-beta or IFN-gamma, and they neutralized the antiviral activity of the patient's endogenous IFN-alpha. The IFN-alpha-binding activity was restricted to the IgG1 subclass in a nonmonoclonal manner. Whereas the PRCA repeatedly responded to immunosuppression with high-dose cyclosporin A (CSA) and CSA plus plasmapheresis, IFN antibody production continued during treatment with cyclophosphamide and CSA. Serological analysis revealed past infection with parvovirus B19 and persistent B19 IgM titers. Antibody-mediated impairment of the IFN-alpha system might have favored the development of both PRCA and the various cutaneous carcinomas in this patient.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903312     DOI: 10.1007/bf01714905

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  20 in total

1.  Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin.

Authors:  W A McGuire; H H Yang; E Bruno; J Brandt; R Briddell; T D Coates; R Hoffman
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

Review 2.  Biotherapy with interferon--1988.

Authors:  R A Figlin
Journal:  Semin Oncol       Date:  1988-12       Impact factor: 4.929

3.  Strategy for the treatment of hairy cell leukemia.

Authors:  F Porzsolt; A Raghavachar; W Digel; A Raghavachar; C R Bartram; H Heimpel
Journal:  Leukemia       Date:  1987-04       Impact factor: 11.528

4.  Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia.

Authors:  R W Armstrong; M J Gurwith; D Waddell; T C Merigan
Journal:  N Engl J Med       Date:  1970-11-26       Impact factor: 91.245

Review 5.  Hematologic and hematopoietic consequences of B19 parvovirus infection.

Authors:  N Young
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

6.  Patient with circulating antibodies to alpha-interferon.

Authors:  K E Mogensen; P Daubas; I Gresser; D Sereni; B Varet
Journal:  Lancet       Date:  1981-11-28       Impact factor: 79.321

7.  Antibodies to alpha-interferon in a patient with systemic lupus erythematosus.

Authors:  S Panem; I J Check; D Henriksen; J Vilcek
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

8.  The detection of antibodies to recombinant interferon alfa-2a in human serum.

Authors:  U Hennes; W Jucker; E A Fischer; T Krummenacher; A V Palleroni; P W Trown; S Linder-Ciccolunghi; M Rainisio
Journal:  J Biol Stand       Date:  1987-07

9.  Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).

Authors:  B J Cohen; P P Mortimer; M S Pereira
Journal:  J Hyg (Lond)       Date:  1983-08

Review 10.  [Immunization against interferon in man].

Authors:  B Pozzetto; K E Mogensen
Journal:  Pathol Biol (Paris)       Date:  1986-12
View more
  4 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

3.  Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.

Authors:  L E Rönnblom; E T Janson; A Perers; K E Oberg; G V Alm
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

4.  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

Authors:  C Ross; M Svenson; M B Hansen; G L Vejlsgaard; K Bendtzen
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.